Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07454226) titled 'ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Condition:
Ph-Like
Acute Lymphoblastic Leukemia
Intervention:
Drug: Olverembatinib
Drug: Ruxolitinib
Drug: Venetoclax
Drug: Chemotherapy Regimen
Drug: Blinatumomab
Procedure: CAR-T Cell Therapy
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: March 1, 2026
Target Sa...